Our drug candidates need further derisking to attract capital. I'm confident phase 2 results will do that.
I don't understand why we couldn't wait for topline data . Management had it on record that funding why sufficient for phase 2 trial. Surely $16M could have gone a long way. Couldn't it?
Our drug candidates need further derisking to attract capital....
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $26.22M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.5¢ | $6.663K | 1.332M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 46 | 38364906 | 0.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.6¢ | 20752393 | 17 |
View Market Depth
| Last trade - 16.10pm 17/05/2024 (20 minute delay) ? |
|
|||||
|
Last
0.5¢ |
Change
0.000 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 0.6¢ | 0.6¢ | 0.5¢ | 1264516 | ||
| Last updated 14.17pm 17/05/2024 ? | |||||
| ATH (ASX) Chart |